Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 11/20 | 0.36 |
| ▸ | ALPP | P05187 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28724377 | 1.00 | PRKD1 (0.37) | PRKD1MMEALPPRIPK1MAPT | |
| SCHEMBL28724388 | 1.00 | PRKD1 (0.37) | PRKD1MMEALPPRIPK1MAPT | |
| SCHEMBL29707801 | 0.94 | PRKD1 (0.38) | PRKD1MMEALPPMAPTJAK2 | |
| SCHEMBL23041519 | 0.94 | PRKD1 (0.38) | PRKD1MMEALPPMAPTJAK2 | |
| SCHEMBL23041527 | 0.94 | PRKD1 (0.38) | PRKD1MMEALPPMAPTJAK2 | |
| SCHEMBL23041699 | 0.94 | PRKD1 (0.38) | PRKD1MMEALPPMAPTJAK2 | |
| SCHEMBL29707865 | 0.94 | PRKD1 (0.38) | PRKD1MMEALPPMAPTJAK2 | |
| SCHEMBL23051994 | 0.92 | PRKD1 (0.37) | PRKD1MMEALPPMAPTSMYD3 | |
| SCHEMBL23041413 | 0.90 | MME (0.36) | PRKD1MMEALPP | |
| SCHEMBL23041496 | 0.90 | MME (0.36) | PRKD1MMEALPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2022-09-29 | — | — | US | disclosed |
| EP-4021572-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| CN-114341132-A | Substituted 1, 3-phenylheteroaryl derivatives and their use in the treatment of diseases | 诺华股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306617-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | CFTR, TMEM161A, TMEM164 | PRKD1 1733/4885MME 4464/4885ALPP 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.